Emerging Therapeutics in the U.S. Colorectal Cancer Markets

 

Regular Price: USD 4,950

Special Price USD 3,465

30% OFF

* Required Fields

Regular Price: USD 4,950

Special Price USD 3,465

PAY BY INVOICE

Be the first to review this product

Emerging Therapeutics in the U.S. Colorectal Cancer Market is a rapidly progressing field that is set to generate over $2 billion in revenue in the coming years. The market has witnessed unprecedented growth with the launch of a new segment and as a result competition has increased in the cytotoxic market. The dynamics of this market are changing rapidly and the forecast through 2011 highlights the major changes. This study includes patient forecasts, pipeline analysis and individual product revenue forecasts.

Table of Contents

Emerging Therapeutics in the U.S. Colorectal Cancer Markets, U.S. Total Market for Colorectal CancerExecutive SummaryExecutive Summary - Updated 4/2006Research Scope and MethodologyScope and SegmentationResearch MethodologyDisease OverviewIntroductionEtiologyScreeningDiagnosis and StagingTreatment OverviewPatient ForecastsIncidence and Staging ForecastsPatient Forecasts by Line of TherapyUnmet Need Population ForecastsTotal Market ForecastsTotal Market Forecasts - Updated 4/2006Market Share Analysis - Updated 4/2006Adjuvant Therapy Forecasts - Updated 4/2006First-line Therapy Forecasts - Updated 4/2006Second and Third-line Therapy Forecasts - Updated 4/2006General Market TrendsIndustry ChallengesMarket DriversMarket RestraintsFrost & Sullivan AwardsCompany of the Year AwardProduct of the Year AwardEntrepreneurial Company of the Year AwardProduct Differentiation Innovation of the Year AwardBest Bang for the Buck AwardEmerging Therapeutics in the U.S. Colorectal Cancer Markets, U.S. Cytotoxic Therapies Market for Colorectal CancerOverviewIntroduction - Updated 4/2006Market Engineering MeasurementsForecasts and TrendsDosage and Cost of Therapy Estimations - Updated 4/20065-FU Forecasts - Updated 4/2006Camptosar/Generic Forecasts - Updated 4/2006Eloxatin - Updated 4/2006Xeloda Forecasts - Updated 4/2006Competitive AnalysisCompetitive Structure - Updated 4/2006Market Share Analysis - Updated 4/2006Product AnalysisPipeline Analysis - Updated 4/2006Emerging Therapeutics in the U.S. Colorectal Cancer Markets, U.S. Targeted Therapies Market for Colorectal CancerOverviewIntroduction - Updated 4/2006Market Engineering MeasurementsAngiogenesis PathwayMechanism of ActionProduct AnalysisPipeline Analysis - Updated 4/2006EGF PathwayMechanism of ActionProduct AnalysisPipeline Analysis - Updated 4/2006Cell Proliferation/Apoptosis PathwayMechanism of ActionPipeline Analysis - Updated 4/2006Immune Response PathwayMechanism of ActionPipeline Analysis - Updated 4/2006Revenue ForecastsDosage and Cost of Therapy Estimations - Updated 4/2006Avastin Forecasts - Updated 4/2006Erbitux Forecasts - Updated 4/2006Panitumumab Forecasts - Updated 4/2006Competitive AnalysisCompetitive Structure - Updated 4/2006Market Share Analysis - Updated 4/2006Emerging Therapeutics in the U.S. Colorectal Cancer Markets, AppendixDecision Support DatabasesPhysiciansTotal Male PopulationTotal Female PopulationMortality of Colorectal CancerRed Meat Consumption




Related Research

Release Date : 15-Sep-17

Region : North America

Release Date : 15-Sep-17

Region : North America

Release Date : 13-Sep-17

Region : North America

Release Date : 13-Sep-17

Region : North America

Release Date : 13-Sep-17

Region : North America

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.